

10/534082
JC06 Re PCT/PTO 05 MAY 2003

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: Based on PCT/JP2003/014138
Filed: Intl. Filing 06 NOVEMBER 2003
1st Inventor: Shuji HINUMA
For: Novel FPRL1 Ligands and Use Thereof
Atty. Dkt. No. 3118 USOP

Art Unit: tba
Examiner: tba
Allowed:
Batch:
Paper No.:

Information Disclosure Statement

MAIL STOP PCT
P.O. Box 1450
Commissioner for Patents
Alexandria, VA 22313-1450

Sir:

Pursuant to 37 CFR §1.56, 1.97 and 1.98, Applicants request consideration of the references listed on the attached Forms PTO/SB/08A and PTO/SB/08B. A legible copy of each listed reference is herewith being provided to the Examiner.

This Information Disclosure Statement is being submitted within 3 months of the filing date of the above-identified application, and before the mailing date of the first Office Action on the merits, thus, no certification or fee is required.


Applicants respectfully request that the listed documents be considered by the Examiner and formally be made of record in the present application and that an initialed copy of the attached form PTO/SB/08A be returned in accordance with MPEP §609.

Should the Examiner believe that a conference with Applicants' attorney would advance prosecution of this application, the Examiner is respectfully requested to call Applicants' attorney.

Dated: 5/2/05

(847) 383-3372
(847) 383-3391

Respectfully submitted,



Mark Chao, Ph.D., Reg. No. 37,293
Elaine M. Ramesh, Ph.D., Reg. No. 43,032
Attorney for Applicants
Customer No. 23115

Takeda Pharmaceuticals North America, Inc.
Intellectual Property Department
475 Half Day Road
Lincolnshire, IL 60069 USA

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number	Based on PCT/JP2003/044138
Filing Date	Intl. Filing 06 NOVEMBER 2003
First Named Inventor	Shuji HINUMA
Art Unit	tba
Examiner Name	tba
Attorney Docket Number	3118 USOP

Sheet	1	of	3
-------	---	----	---

U. S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ³ *Number ⁴ *Kind Code ⁵ (if known)				
	A1	WO 03/106683 A1 - Abstract only	12/24/2003	Takeda Chemical Industries		
	A2	WO 2004/008141 A1 - Abstract only	01/22/2004	Takeda Chemical Industries		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for form 1449/PTO		Complete if Known 10/534082	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	Based on PCT/JP2003/014138
		Filing Date	Intl. Filing 06 NOVEMBER 2003
		First Named Inventor	Shuji HINUMA
		Art Unit	tba
		Examiner Name	tba
Sheet 2	of 3	Attorney Docket Number	3118 USOP

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	A3	P.M. MURPHY, et al., "A Structural Homologue of the N-Formyl Peptide Receptor", The Journal of Biological Chemistry, (1992), pp. 7637-7643, Vol. 267, No. 11.	
	A4	Y. LE, et al., "Receptors for Chemotactic Formyl Peptides as Pharmacological Targets", International Immunopharmacology, (2002), pp. 1-13, Vol. 2.	
	A5	Y. LE, et al., "Amyloid Beta42 Activates a G-Protein-Coupled Chemoattractant Receptor, FPR-Like-1", The Journal of Neuroscience, (2001), RC123, 1 of 5, Vol. 21.	
	A6	H. YAZAWA, et al., "Beta Amyloid Peptide (AlphaBeta42) is Internalized via the G-Protein-Coupled Receptor FLPL1 and Forms Fibrillar Aggregates in Macrophages", The FASEB Journal, (2001), pp. 2454-2462, Vol. 15.	
	A7	T. CHRISTOPHE, et al., "The Synthetic Peptide Trp-Lys-Tyr-Met-NH2 Specifically Activates Neutrophils...", The Journal of Biological Chemistry, (2001), pp. 21585-21593, Vol. 276, No. 24.	
	A8	A. BETTEN, et al., "A Proinflammatory Peptide from Helicobacter Pylori Activates Monocytes to Induce Lymphocyte Dysfunction and Apoptosis", The Journal of Clinical Investigation, (2001), pp. 1221-1228, Vol. 108, No. 8.	
	A9	DE YANG, et al., "Human Dendritic Cells Express Functional Formyl Peptide Receptor-Like-2 (FPRL2) Throughout Maturation", Journal of Leukocyte Biology, (2002), pp. 598-607, Vol. 72.	
	A10	M. PERRETTI, et al., "Endogenous Lipid-and Peptide-Derived Anti-Inflammatory Pathways Generated with Glucocorticoid and Aspirin Treatment Activate the Lipoxin A4 Receptor", Nature Medicine, (2002), pp. 1296-1302, Vol. 8, No. 11.	
	A11	Y. CUI, et al., "Potential Role of the Formyl Peptide Receptor-Like 1 (FPRL 1) in Inflammatory Aspects of Alzheimer's Disease", Journal of Leukocyte Biology, (2002), pp. 628-635, Vol. 72.	
	A12	S.M. SHAWAR, et al., "Peptides From the Amino-Terminus of Mouse Mitochondrially Encoded NADH Dehydrogenase Subunit 1 are Potent Chemoattractants", Biochemical and Biophysical Research Communications, (1995), pp. 812-818, Vol. 211, No. 3.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

JCO6 Rec'd PCT/PTO 05 MAY 2005

PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known	
		Application Number	Based on PCT/JP2003/014138
		Filing Date	Intl. Filing 06 NOVEMBER 2002 10/534082
		First Named Inventor	Shuji HINUMA
		Art Unit	tba
		Examiner Name	tba
Sheet 3	of 3	Attorney Docket Number	3118 USOP

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	A13	H. CARP, "Mitochondrial N-Formylmethionyl Proteins as Chemoattractants for Neutrophils", J. Exp. Med., (1982), pp. 264-275, Vol. 155.	
	A14	S. ANDERSON, et al., "Sequence and Organization of the Human Mitochondrial Genome", Nature, (1981), pp. 457-465, Vol. 290.	
	A15	Y. LE, et al., "Formyl-Peptide Receptors Revisited", Trends in Immunology, (2002), pp. 541-548, Vol. 23, No. 11.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.